Background: Aberrant CD40 ligand (CD154) expression occurs on both T cells and B cells in human lupus patients, which is suggested to enhance B cell CD40 signaling and play a role in disease pathogenesis. Transgenic mice expressing CD154 by their B cells (CD154
Introduction
Interactions between CD40 expressed by B cells and its ligand CD154, expressed by antigen (Ag)-activated CD4 + helper T cells, promotes BCR-induced B cell proliferation and survival, which is essential for isotype switching and germinal center (GC) formation [1, 2, 3, 4, 5, 6] . Interrupting CD40 and CD154 interactions prevents the development of both T cell-dependent (TD) humoral immune responses and cell-mediated immune responses [7] . Agonistic CD40 mAbs are also potent immune adjuvants for both shortlived humoral-immunity to T cell-independent Ags [8, 9] and cellular immune responses to viruses and tumors [10, 11, 12] . However, CD40 agonists given during TD immune responses actually ablate GC formation, induce a pattern of extrafollicular B cell differentiation in the spleen and lymph nodes, prematurely terminate humoral immune responses, block the generation of B cell memory, and prevent the generation of long-lived bone marrow plasma cells [13] . Consistent with this, ectopic CD154 expression by B cells in transgenic mice (CD154   TG   ) terminates germinal center responses prematurely and leads to augmented plasma cell production in T cell areas [14, 15] . Expression of the CD154 transgene in these mice is driven by immunoglobulin (Ig) gene promoter and enhancer elements, resulting in B cell-specific expression [14, 15] . B cell CD154 expression has a precedent in human disease, as it is expressed by both T cells and B cells in systemic lupus erythematosus (SLE) patients and in a mouse model of lupus [16, 17, 18] , with ectopic B cell expression of CD154 in aged hemizygous CD154 TG mice leading to intestinal inflammation [19] or SLE-like autoimmunity including anti-DNA autoAbs and glomerulonephritis [20] . While a certain level of B cell CD40 signaling can exacerbate the development or severity of autoimmune disease, these studies collectively suggest that the fate of Agspecific B cells is dramatically altered by the extent of CD40 ligation, with heightened CD40 signaling potentially representing a physiological means to limit the duration and intensity of immune responses.
CD22 negatively regulates transmembrane signals in B cells through association with the potent intracellular phosphatases SHP-1 and SHIP [21, 22, 23, 24] . B cells from CD22 2/2 mice are markedly hyper-responsive to CD40 signals, whereby their ex vivo stimulation with agonistic CD40 mAb induces a much greater degree of proliferation relative to wild type (WT) B cells [25] . As such, potent in vivo signals provided by constitutive CD40 signaling combined with CD22 deficiency may alter the duration and intensity of immune responses, size of the autoreactive B cell pool, and autoAb production levels. To test this, CD22
2/2 mice homozygous for the CD154 transgene (CD154 TG CD22 2/2 ) were generated. Remarkably, the defining in vivo characteristic of CD154 TG CD22 2/2 mice was a dramatic expansion in regulatory B10 cells that were competent to express IL-10 [26, 27] , and meager IgG production against both foreign and self Ags. Thus, enhancing CD40 signaling limited the duration and intensity of humoral immune responses likely by driving the expansion of B10 cells, a B cell subset that is also found in humans [28] . Inducing such an expansion of B10 cells may be particularly therapeutic in autoimmune syndromes such as SLE where aberrant CD154 expression contributes to inflammation and the generation of pathogenic isotype-switched B cells.
Methods

Ethics statement
All animal studies and procedures were approved by the Duke University Institutional Animal Care and Use Committee (approved IACUC protocol #A008-08-01; Duke University PHS Animal Welfare Assurance No. A3195-01).
Mice
CD22
2/2 mice, backcrossed with C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) for $8 generations were previously described [25] . CD154 transgenic mice [20] were crossed to homozygosity and referred to as CD154 TG mice. Double mutant mice were generated by interbreeding the F1 offspring of CD22 2/2 and CD154 TG mice, with CD154 TG CD22 2/2 mice maintained as homozygous at both genetic loci by sibling matings. C57BL/6 WT control mice were purchased from either The Jackson Laboratory (Bar Harbor, ME) or NCI Frederick (Bethesda, MD). Bcl-xL transgenic mice [29] were a kind of Dr. Michael Farrar (University of Minnesota, Minneapolis, MN). Unless otherwise indicated, all mice used in these studies were between 8 and 14 weeks of age. Mice were housed in a specific pathogen-free barrier facility.
Tissue harvest, flow cytometry and Abs
Single-cell suspensions were isolated from spleen, BM, peripheral LNs, and the peritoneal cavity. Spleen and BM RBCs were depleted using ammonium chloride-Tris lysis buffer. Blood was obtained by retroorbital puncture. Leukocytes (0.5-1610 6 ) were stained at 4uC using predetermined optimal concentrations of Abs for 30 min, then analyzed by flow cytometry. Blood RBCs were lysed following surface staining using BD FACS TM Lysing Solution (BD Biosciences). Cells were analyzed on a FACSCanto II flow cytometer (BD Biosciences). Abs against surface or intracellular mouse proteins were as follows: B220 (RA3-6B2), CD21/35 (7G6), CD24 (M1/69), CD25 (PC61), GL-7 (Ly-77), CD154 (MR1), CD23 (B3B4), CD44 (IM7), CD1d (1B1), CD90. 
Experimental autoimmune encephalomyelitis (EAE) experiments
Purified spleen B cells from CD154 TG CD22 2/2 donor mice were surface labeled with CD1d and CD5 mAbs, with CD1d hi CD5 + and CD1d lo CD5 2 B cell populations isolated using a FACSVantage SE flow cytometer with purities of 95-98%. 1610 6 cells were either directly transferred i.v. into WT recipient mice, or were first cultured with agonistic CD40 mAb for 48 h with LPS added during the final 5 h of culture, then washed and transferred. One day after cell transfers, EAE was induced in recipient mice with clinical signs of EAE scored daily as described [30, 31] .
Immunizations
In some experiments, WT, CD22 2/2 , CD154 TG , and CD154 TG CD22 2/2 mice were immunized i.p. with 100 mg DNP-KLH in CFA, and then boosted on day 21 with DNP-KLH in IFA. Serum Ag-specific Ig levels were determined by ELISA. Alternatively, the mice were immunized i.p. with 50 mg 4-hydroxy-3-nitrophenyl acetyl-conjugated chicken c-globulin (NP 8 CGG) in alum, with spleens were harvested on day 10 and the splenocytes stained with GL-7 and B220 mAbs, with doublepositive B cells identified by flow cytometry. In other experiments where adjuvant was excluded, WT mice were immunized i.p. with 100 mg DNP-KLH in PBS alone, and then boosted on day 21 with DNP-KLH in PBS alone.
ELISAs and ELISPOT assays
Serum IgM and IgG levels and serum IgM and IgG autoAb levels were determined by ELISA. 96-well microtiter plates (Costar, Cambridge, MA) were coated overnight at 4uC with either 5 mg/ml goat anti-mouse Ig(H+L) Abs (BD Pharmingen), 2 mg/ml of calf thymus double-or single-stranded DNA (Sigma-Aldrich, St. Louis, MO), or 5 mg/ml calf thymus Type II-AS histone proteins (SigmaAldrich). Single stranded DNA was obtained by boiling calf thymus dsDNA in 16 SSC for 10 minutes, followed by immediate immersion in ice. Coated plates were blocked for 1 hr at RT with Tris-buffered saline containing 1% BSA and 2% gelatin, then incubated for 1 hr at RT with pre-determined concentrations of sera diluted in Tris-buffered saline containing 1% BSA. Bound Abs were detected with alkaline phosphatase-conjugated goat antimouse IgG or IgM Abs (Southern Biotechnology Associates, Birmingham, AL). Ig levels were determined by quantifying serum titers against known standards (purified mouse IgM or IgG, Southern Biotechnology Associates). Alkaline phosphatase activity was detected using p-nitrophenyl phosphate substrate (SigmaAldrich) at a wavelength of 405 nm.
DNP-specific Ab levels were determined by ELISA as described [32] . Briefly, sera from DNP-KLH-immunized mice were diluted 1:1000 for analysis using ELISA plates coated overnight at 4uC with 100 mg/ml DNP-BSA (Calbiochem-Novabiochem Corp.). Bound Ag-specific IgM and IgG Abs were then detected with alkaline phosphatase-conjugated goat anti-mouse IgM or isotypespecific IgG Abs, as above. Ab-secreting cell frequencies were determined by ELISPOT assay as described [33] . Briefly, dilutions of spleen B cells were cultured in DNP-BSA-coated Multiscreen HTS IP plates (Millipore, Bedford, MA) for 5 hours. After extensive washing, the plates were incubated with alkaline phosphatase-conjugated goat anti-mouse IgG Ab, with the spots counted using a dissecting microscope.
CD22 mAb treatment
The MB22-10 mAb and an isotype-matched control mAb (250 mg/mouse) were given to mice i.v. as previously described to deplete CD1d hi CD5 + B cells [34] and IL-10-competent B10 cells [31] .
Statistical analysis
All data are shown as means (6SEM), unless otherwise noted. The Student's t-test was used to determine the significance of differences between sample means.
Results
B cell phenotype and numbers in CD154
TG CD22 2/2 mice
The biological effects of CD22-deficiency are B cell intrinsic as CD22 expression is only expressed by B cells [25] . Furthermore, transgenic CD154 was specifically expressed by B cells in homozygous CD154
TG mice, but not on other lymphocytes or other hematopoietic cells in the blood or spleen ( Figure 1A -B, data not shown) as previously documented for hemizygous CD154 TG mice [20] . To examine the combined effects of B cell intrinsic CD154 expression and CD22-deficiency, CD154 TG CD22 2/2 mice as assessed in frozen spleen sections ( Figure 1D ), as published [24, 34, 35] . Remarkably, the MZ B cell population was restored in CD154 TG CD22 Figure 1G ).
In contrast to CD40 stimulation, CD22 2/2 B cells undergo apoptosis following extensive BCR ligation due to blocked cell cycle progression [25] . Likewise, proliferation of B cells from CD154 TG CD22
2/2 mice was profoundly deficient following BCR ligation with F(ab)9 2 anti-IgM Ab and nearly identical to the defect of CD22 2/2 B cells ( Figure 1F 2/2 B cells uniquely proliferated at significant levels as assessed by CFSE dilution ( Figure 1H ). Collectively, these data demonstrate that B cells in CD154 TG
CD22
2/2 mice are capable of receiving CD40 and additional costimulatory signals that promote B cell activation, survival, and proliferation.
Importantly, transgenic CD154 engagement of CD40 in CD154 TG and CD154 TG CD22 2/2 mice appears to be primarily mediated through cis (same cell) interactions on B cells, since mixed bone marrow chimeras derived from WT and CD154 TG donors exhibit enhanced Ab production specifically from CD154 TG B cells [14, 15] . Also, activation markers on dendritic cells are not altered in CD154 TG mice relative to WT mice [14, 15] . In addition, despite being hyper-responsive to stimulation with agonistic CD40 mAb, CFSE-labeled CD22 Figure 3 . Figure 2C ). Remarkably, classical GC structures were absent in the spleens of both CD154 TG and CD154 TG CD22 2/2 mice after the boost phase of DNP-KLH immunization as assessed by in situ immunofluorescence staining of frozen spleen sections ( Figure 2C) Figure 1D -E), a novel subset of regulatory IL-10-producing B cells termed 'B10' cells was recently identified within the spleen CD1d hi CD5
+ subpopulation [27, 30, 36, 37] . Through in vivo adoptive transfer and depletion experiments, B10 cells were found to suppress autoimmunity and inflammation in mouse models of disease [30, 37, 38] . Remarkably, B10 cell frequencies and numbers were increased dramatically within the spleens of CD154 TG CD22 2/2 mice, with 16-, 15-, and 4.1-fold higher B10 cell numbers than in WT, CD22 2/2 , or CD154 TG mice, respectively ( Figure 3A and Table 1 ). B10 cell numbers in tissues other than spleen were modest in all four genotypes ( Figure 3A ). B10 cells from WT, CD22 Figure 3C and Table 1 ). Figure 4C , upper panel).
B10 cells in CD154
The frequency of IL-10-competent B10 cells among CD1d hi CD5 + B cells is enhanced by B10pro cell maturation in vitro (Figure 3 ) as described [27] Figure 4C , lower panel). As such, B10 cells from CD154 TG CD22 2/2 mice had a regulatory capacity when transferred into WT mice.
B10 cell depletion in vivo enhances IgG production in WT mice
A mAb that engages the ligand binding domains of CD22 (MB22-10 mAb) preferentially depletes spleen B10 cells and B cells with a CD1d hi phenotype in WT mice [31, 34] . Likewise, depletion of the CD1d hi CD5 + spleen B cell population that harbors most B10 cells was dramatic (.70%) in WT mice 7 days following a single dose of MB22-10 mAb relative to control mAb ( Figure 5A ). Spleen B10 cell frequencies and numbers were also reduced .60% in MB22-10 mAb-treated mice relative to control mAb treated mice ( Figure 5B ). Follicular CD1d lo CD5 2 and other CD19
+ non-B10 B cell frequencies and numbers were not significantly affected by MB22-10 mAb treatment ( Figure 5A -B, and data not shown). Thus, CD22 mAb treatment efficiently depleted spleen B10 cells while leaving most other spleen B cells intact.
Effective B10 cell depletion by MB22-10 mAb in WT mice provides a system to verify that the expansion of B10 cells in CD154 TG CD22 2/2 mice contributes to their modest IgG responses. Since CD154 TG CD22 2/2 mice do not express CD22 and are thus not amenable to the use of CD22 mAb, it was determined whether B10 cell depletion by MB22-10 mAb would enhance IgG responses in WT mice immunized with a TD Ag in the absence of adjuvant. DNP-KLH immunization induced significant primary and secondary (day 21 boost) DNP-specific IgM responses in control mAb-treated WT mice, while DNPspecific IgG responses rose only slightly above background levels ( Figure 5C ). By contrast, MB22-10 mAb-treated mice generated normal Ag-specific IgM responses and robust DNP-specific IgG1, IgG2c, IgG2b, and IgG3 Ab responses that remained high. MB22-10 mAb treatment also significantly expanded the frequency of spleen IgG-secreting B cells in comparison with control mAbtreated mice ( Figure 5D ). Thereby, B10 cell depletion dramatically enhanced IgG immune responses in WT mice.
Discussion
CD154 is expressed at relatively high levels by both T cells and B cells in SLE patients and in a mouse model of lupus, which is proposed to drive CD40 signaling, B cell hyperactivity, and autoAb production [16, 17, 18] . Although CD154 expression by B cells in the current study appears lower by comparison, the combination of CD154 expression and CD22 deficiency significantly enhanced B cell responses to CD40 signaling (Figure 1) . B cell CD154 expression in CD154 TG CD22
2/2 mice also led to a remarkable 16-fold expansion of the regulatory B10 cell subset relative to WT mice. B10 cells normally represent only 1-3% of spleen B cells in WT mice [30, 37] . In fact, B10 cells alone represented 16% of spleen B cells in CD154 TG CD22 2/2 mice, while B10+B10pro cells represented 39% of spleen B cells. B10 cell expansion also paralleled a dramatic reduction in B cell isotype switching, with lower IgG Ab and autoAb levels in CD154 TG CD22 2/2 mice than were present in the parental mouse lines, even after immunization using a strong TD Ag in adjuvant. IgG deficiency was not observed in CD154 TG mice where spleen B10 cells were only expanded 3.8-fold and total spleen B cells were expanded 3.6-fold ( Figure 3A and Table 1 ). Thus, heightened CD40 signaling through the combination of chronic CD154 expression and CD22-deficiency drove the in vivo expansion of regulatory B10 cells with functional activity, and limited the intensity of IgG immune responses, both of which may limit the pathogenic consequences of autoimmunity.
B cell negative regulation of immune responses through the production of IL-10 has been demonstrated in EAE [30, 39, 40, 41] and other mouse models of autoimmunity and inflammation [30, 36, 42, 43, 44, 45] . These B cells are called ''B10 cells'' because IL-10 secretion is required for their negative regulatory function, and other B cell subsets with their own unique regulatory properties may also exist [26] . B10 cells have a potent capacity to down-modulate immune responses during adoptive transfer experiments [30, 37, 38, 46] , a property clearly retained by CD154 TG CD22 2/2 B10 cells ( Figure 4C ). Spleen B10 cells are predominantly contained within the phenotypically unique CD1d hi CD5 + subpopulation and are presumed to be functionally mature since they are competent to express quantifiable IL-10 after 5 h of ex vivo stimulation [30, 37] . B cell regulatory functions are also enhanced by ex vivo CD40 or LPS stimulation in inflammation and autoimmunity models [40, 47, 48, 49] , although CD40 or TLR signaling are not required for B10pro or B10 cell generation [27] . However, CD40 signaling and LPS exposure can induce mouse B10pro cells to mature into functional IL-10-competent B10 cells [27] , while LPS or CpG exposure can induce B10 cells to secrete IL-10. Thus, B10pro and B10 cells provide a fundamental linkage between the adaptive and innate immune systems. B10 cells in CD154 TG
CD22
2/2 mice were phenotypically and functionally similar to B10 cells in WT mice, including their characteristic high levels of CD19 expression and ability to respond to LPS and CD40 signals (Figure 3; [37] ). The current studies clearly demonstrate that enhanced B cell CD40 signaling in vivo leads to a remarkable phenotypic outcome characterized by B10 and B10pro cell expansion, with suppressed isotype switching and IgG autoAb production that may be attributable to the regulatory activity of these cells through their production of IL-10.
Depleting the relatively small number of endogenous B10 cells in wild type mice significantly enhanced isotype switching and IgG production in response to immunization in the absence of adjuvant ( Figure 5C-D) . B10 cell depletion by CD22 mAb also enhances cellular immunity during EAE initiation [31] . By contrast, expanded B10 cell numbers in CD154 TG CD22
2/2 mice paralleled their IgG-deficient phenotype. Further supporting a mechanistic explanation for reduced IgG production in + B cell subsets used for adoptive transfer experiments (Figure 4A ), the fact that it is not possible to quantify Ag-specific B10 cell frequencies, signaling or continuous CD154 internalization, as also occurs in CD154 TG mice ( Figure 1A,F) , as the explanation for this observation. It is also unlikely that B10 cells inhibited B cell differentiation directly since serum IgM levels were elevated in CD154 TG CD22 2/2 mice. Thus, B10 cell depletion in WT mice and expansion in CD154 TG CD22 2/2 mice had the predicted biologic effects of facilitating and inhibiting, respectively, IgG immune responses. Agonistic CD40 mAb treatment in vivo ''short-circuits'' humoral immunity and impairs IgG production, GC formation, and B cell memory [13] . Tsubata and colleagues have also found accelerated termination of GC reactions to T cell-dependent Ags in hemizygous CD154 TG mice, although IgG production remained robust [14, 15] . CD40 agonists also induce extrafollicular B cell differentiation. The ''short circuiting'' of IgG responses described above under robust CD40 ligation conditions (e.g., agonistic CD40 mAb) may be explained in part by the expansion and/or maturation of B10 and B10pro cells, as occurred in CD154 TG CD22 2/2 mice. Consistent with this, B10 cells proliferate more rapidly than non-B10 cells following mitogen stimulation [27] . Therefore, the rapid expansion of Ag-specific B10 cells within extrafollicular foci of CD154 TG
2/2 mice may result in Ag consumption and/or clearance by IgM before the initiation of germinal center reactions and IgG production. Alternatively, B10 cells may indirectly regulate germinal center formation by altering TD immunity or the ability of dendritic cells to act as Ag-presenting cells during T cell activation [31] , which are required for efficient B cell isotype switching.
Treatment of WT mice with the MB22-10 mAb that blocks CD22 ligand binding preferentially depleted spleen B10 and CD1d hi CD5 + B cells, but not follicular B cells ( Figure 5A ,B) as described [31] . While CD22 ligand binding is needed for the optimal survival of some B cell populations, such as MZ B cells [34, 35, 50] , B10 cell development was normal in CD22 2/2 mice and dramatically expanded in CD154 TG CD22 2/2 mice. As such, CD22 ligation with this particular mAb may induce signals that promote B10 cell apoptosis, alter their maturation, and/or affect their tissue distribution. B10 cell localization may be critical for function since spleen CD1d hi B220 + B cells were identified in both the MZ and follicular regions ( Figure 1D ), suggesting that B10 cells + and B10 cells. Seven days after WT mice were given CD22 or control mAb, splenocytes were isolated and cultured in the presence of L+PIM for 5 h followed by cell surface CD19, CD1d and CD5, and intracellular IL-10 staining, with flow cytometry analysis. IL-10 2/2 mice given control mAb were also evaluated for comparison. inhabit both sites. In support of this, spleen MZs were undetectable in CD22 2/2 mice, yet these mice had significant numbers of B10 and CD1d hi B220
+ B cells scattered throughout their follicles. Intrafollicular CD1d hi B cells were especially prominent in CD154 TG CD22 2/2 mice ( Figure 1D ). In any case, B cell depletion by the MB22-10 mAb is not dependent on Abdependent cellular cytotoxicity or complement activation [34] . In addition, the MB22-10 mAb impairs malignant B cell survival in mice [34] . Therefore, therapeutic B10 cell depletion may be useful for enhancing IgG responses, or for the treatment of tumors and immunosuppression.
Foxp3 + CD25 + Treg cell numbers were normal in both CD154 TG and CD154 TG CD22 2/2 mice (Table 1) . Similarly, B10 cells do not appear to directly regulate Treg cell numbers in an EAE model, where these two regulatory subsets function independently [31] . This suggests that the potential suppressive effect of B10 cells on IgG production did not result from Treg cell expansion. By contrast, the adoptive transfer of CD1d hi CD5 + B cells from wild type mice into CD19-deficient NZB/W F1 mice leads to a significant increase in Treg numbers [46] . While these results suggest that B10 cells could drive Treg cell expansion, the majority of spleen CD1d hi CD5 + B cells are not B10pro or B10 cells [27] . Thus, the adoptive transfer of non-B10 cells may independently promote CD4
+ Treg cell generation. This possible explanation may also apply to studies suggesting that Breg cellinduced inhibition of inflammation is partly driven by Breg cellinduced Treg cell expansion. Nonetheless, spleen IL-10-competent T cell numbers were significantly increased in both CD154 TG and CD154 TG CD22 2/2 mice relative to WT and CD22 2/2 mice, in parallel with increased CD4
+ and CD8 + memory T cell numbers ( Table 1 ). The increase in IL-10-competent and memory T cells may therefore result from B cell CD154 expression. It is unlikely that the increase in IL-10-competent and memory T cells drives B10 cell expansion since B10 cell expansion was limited to CD154 TG CD22 2/2 mice. Thus, B cell expression of CD154 appears to have intrinsic effects on B cells as well as extrinsic effects on cellular immunity.
T and B cell CD154 expression in SLE patients is proposed to drive autoimmunity [16, 17, 18] , and a clear role for aberrant CD40 signaling in other inflammatory autoimmune diseases has emerged in recent years [51, 52] . It has also been suggested that chronic CD40 signaling, particularly in patients with SLE, functionally inactivates a subset of regulatory B cells [53] . However, the current studies suggest that B cell CD154 expression may predispose lupus patients towards enhanced B10 cell production. Consistent with this, B10pro cell numbers are expanded in SLE patients, and can be induced to mature and acquire IL-10 competence following agonistic CD40 stimulation [28] . Therefore, constitutive, robust CD40 signals may drive functional B10pro cell expansion and limit the pathogenic consequences of autoimmunity by reducing Ab isotype switching. Moreover, this study predicts that certain combinations of genetic traits that can individually induce autoimmune disease may actually reduce autoimmunity by expanding B10 cell numbers. For example, CD22
2/2 mice produce high-affinity serum IgG autoAbs spontaneously with age [54] , and hemizygous CD154 TG mice can develop relatively mild autoimmunity [19, 20] . B10 cell numbers are also expanded in type 1 diabetes-prone NOD mice, and in lupus-prone MRLlpr and NZB/W F 1 mice, even prior to the appearance of disease [27, 38] . Similarly, blood B10pro cell numbers are expanded significantly in humans with lupus and other autoimmune diseases [28] . The observation that manipulation of the CD40 and CD22 signaling pathways can drive resident B10 cell expansion in vivo also highlights a potential therapeutic benefit for expanding B10 cells in humans to limit the pathogenic consequences of humoral IgG responses to self Ags.
